Structural mechanisms of HIV drug resistance

Annual Review of Pharmacology and Toxicology

Volumn 36, Issue , 1996, Pages 545-571

  Erickson, John W ^a   Burt, Stanley K ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

AIDS; antiviral drug; human immunodeficiency virus (HIV); mutations; protease; reverse transcriptase

Indexed keywords

1 (5 BROMO 2 PYRIDYL) 3 (2 PYRIDYL)THIOUREA; 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; A 77003; ACICLOVIR; AMPRENAVIR; ANTIVIRUS AGENT; ATEVIRDINE; DELAVIRDINE; DIDANOSINE; FOSCARNET; GANCICLOVIR; INDINAVIR; KYNOSTATIN 272; LOVIRIDE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PALINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TROVIRDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

DRUG DEVELOPMENT; DRUG RESISTANCE; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029896214     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pa.36.040196.002553     Document Type: Review

References (74)

1. De Clercq E. 1995. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 38:2491-517
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-26
3. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-22
4. Coffin JM. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 267:483-89
5. Richman DD. 1993. HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 32:149-64
6. Erice A, Balfour HH Jr. 1994. Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review. Clin. Infect. Dis. 18:149-56
7. Richman DD. 1994. Resistance, drug failure, and disease progression. AIDS Res. Hum. Retroviruses 10:901-5
8. De Clercq E. 1994. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47:155-69
9. Emini EA, Byrnes VW, Condra JH, Schleif WA, Sardana VV. 1994. The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors. Arch. Virol. 9:11-17
10. Arnold A, Das K, Ding J, Yadav P, Boyer PL, Hughes SH. 1995. Targeting HIV reverse transcriptase for antiviral drug design against AIDS. Drug Des. Dis. In press
11. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. 1992. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-90
12. Jacobo-Molina A, Ding JP, Nanni RG, Clark AD Jr, Lu XD, et al. 1993. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. USA 90:6320-24
13. Rodgers DW, Gamblin SJ, Harris BA, Ray S, Culp JS, et al. 1995. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 92:1222-26
14. Ren J, Esnouf R, Garman E, Somers D, Ross C, et al. 1995. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 2:293-302
15. Ding JP, Das K, Tantillo C, Zhang W, Clark AD Jr, et al. 1995. Structure of HIV-1 reverse transcriptase in a complex with the nonnucleoside inhibtor α-APA R 95845 at 2.8 Å resolution. Structure 3:365-79
16. Ding J, Das K, Moereels H, Koymans L, Andries K, et al. 1995. Structure of HIV-1 RT/TBIO R 86183 complex reveals similarity in the bindng of diverse nonnucleoside inhibitors. Struct. Biol. 2:407-15
17. Pattabiraman N, Gussio R, Topol I, Burt SK, Erickson JW. 1994. An electronic characterization of a congeneric series of nevirapine analogs. Abstr. Pap. ACS 208:33
18. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleosiide inhibitors. Nat. Struct. Biol. 2:303-8
19. Spence RA, Kati WM, Anserson KS, Johnson KA. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267:988-93
20. Mellors JW, Larder BA, Schinazi RF. 1995. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antivir. News 3:8-13
21. Jacques PS, Wohrl BM, Howard KJ, Le Grice SFJ. 1994. Modulation of HIV-1 reverse transcriptase function in "selectively deleted" p66/p51 heterodimers. J. Biol. Chem. 269:1388-93
22. Mellors JW, Im GJ, Tramontano E, Winkler SR, Medina DJ, et al. 1993. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl) imidazo [4,5,1-jk] [1,4]benzodiazepin-2 (1H)-thione (TIBO R82150). Mol. Pharmacol. 43:1-16
23. Byrnes BW, Sardana W, Schlief WA, Condra JH, Waterbury JA, et al. 1993. Comprehensive mutant enzyme and viral variant assesment of human immunodeficiency virus type-1 reverse transcriptase resistance to non-nucleoside inhibitors. Antimicrob. Agents Chemother. 37:1576-79
24. Balzarini J, Karlsson A, Perez-Perez M-J, Vrang L, Walbers J, et al. 1993. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acids substitutions in the reverse transcriptase. Virology 192:246-53
25. Dueweke TJ, Pushkarskaya T, Poppe SM, Swaney SM, Zhao Q, et al. 1993. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other non-nucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:4713-17
26. Balzarini J, Velazquez S, San-Felix A, Karlsson A, Perez-Perez M-J, et al. 1993. Human immunodeficiency virus type 1-specific [2′,5′bis-O-(tetrabutyl-dimethylsilyl) - β - D - ribofuranosyl]-3′-spiro -5- (4) amino-1′,2′-oxathiole-2′,2′-doxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specfic nononucleoside analogues. Mol. Pharmacol. 43:109-14
27. Gu ZG, Gao Q, Fang HS, Parniak MA, Brenner BG, Wainberg MA. 1994. Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. Leukemia 8(Suppl. 1):5166-69
28. Boyer PL, Tantillo C, Jacobo-Molina A, Nanni RG, Ding JP, et al. 1994. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length: the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad. Sci. USA 91:4882-86
29. Yadav PNS, Yadav JS, Modak MJ. 1994. Nucleoside drug resistance in HIV-1 reverse transcriptase. Nat. Struct. Biol. 2:193-95
30. Tantillo C, Ding JP, Jacobo-Molina A, Nanni RG, Boyer PL, et al. 1994. Locations of anti-AIDS drug-binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. J. Mol. Biol. 243:369-87
31. St. Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, et al. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-59
32. Debouck C 1992. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retroviruses 8:153-64
33. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, et al. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-90
34. Seelmeier S, Schmidt H, Turk V, von der Helm K. 1988. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc. Natl. Acad. Sci. USA 85:6612-16
35. McQuade TJ, Tomasselli AG, Liu L, Karacostas V, Moss B, et al. 1990. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 247:454-56
36. Tomasselli AG, Howe WJ, Sawyer TK, Wlodawer A, Heinrikson RL 1991. The complexities of AIDS: an assessment of the HIV protease as a therapeutic target. Chim. Oggi 9:6-27
37. Huff JR. 1991. HIV protease: a novel chemotherapeutic target for AIDS. J. Med. Chem. 34:2305-14
38. Meek TD. 1992. Inhibitors of HIV-1 protease. J. Enzym. Inhib. 6:65-98
39. Darke PL, Huff JR 1994. HIV protease as an inhibitor target for the treatment of AIDS. Adv. Pharmacol. 25:399-455
40. Mous J, Brun-Vezinet F, Duncan IB, Hanggi M, Jacobsen H, Vella S. 1994. Characterisation of in vivo selected HIV-1 variants with reduced sensitivity to proteinase inhibitor Saquinavir. 10th Int. Conf. AIDS STD, Yokohama, Jpn. p. 515B (Abstr.)
41. Erickson JW. 1995. The not-so-great escape. Nat. Struct. Biol. 2:523-29
42. Wlodawer A, Erickson JW. 1993. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62:543-85
43. Collins JR, Burt SK, Erickson JW. 1995. Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics. Nat. Struct. Biol. 2:334-38
44. Appelt K. 1993. Crystal structures of HIV-1 protease-inhibitor complexes. Perspect. Drug Dis. Des. 1:23-48
45. Fitzgerald PMD, Springer JP. 1991. Structure and function of retroviral proteases. Annu. Rev. Biophys. Biophys. Chem. 20:299-320
46. Abdel-Meguid SS. 1993. Inhibitors of aspartyl proteinases. Med. Res. Rev. 13:731-78
47. Otto MJ, Garber S, Winslow DL, Reid CD, Aldrich P, et al. 1993. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc. Natl. Acad. Sci. USA 90:7543-47
48. Kaplan AH, Michael SF, Wehbie RS, Knigge MF, Paul DA, et al. 1994. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. USA 91:5597-601
49. Ho DD, Toyoshima T, Mo H, Kempf DJ, Norbeck D, et al. 1994. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68:2016-20
50. El-Farrash MA, Kuroda MJ, Kitazaki T, Masuda T, Kato K, et al. 1994. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J. Virol. 68:233-39
51. Anderson B, Kageyama S, Ueno T, Mitsuya H. 1994. In vitro induction of HIV-1 with reduced sensitivity to HIV protease inhibitors, KNI-227 and KNI-272. 10th Int. Conf. AIDS STD, Yokohama, Jpn. p. 516B (Abstr.)
52. Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, et al. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69: 701-6
53. Jacobsen H, Yasargil K, Winslow DL, Craig JC, Krohn A, et al. 1995. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206:527-34
54. Patick AK, Rose R, Greytok J, Bechtold CM, Hermsmeier MA, et al. 1995. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J. Virol. 69:2148-52
55. Emini E, Schleif WA, Graham DA, Deutsch P, Massari F, et al. 1994. Protease inhibitors: cross resistance and in vivo observations. Proc. 3rd Int. Workshop HIV Drug Resist., Kauai, HI. p. 15. London: MediTech Media Ltd. (Abstr.)
56. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, et al. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-71
57. Baldwin ET, Bhat TN, Gulnik S, Liu B, Topol IT, et al. 1995. Structure of HIV-1 protease complexed with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Structure 3:581-90
58. Baldwin ET, Bhat TN, Liu B, Pattabiraman N, Erickson J. 1995. Structural basis of drug resistance for the V82A mutant of HIV-1 protease: backbone flexibility and subsite repacking. Nat. Struct. Biol. 2:244-49
59. Mimoto T, Imai J, Kisanuki S, Enomoto H, Hattori N, et al. 1992. Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally-constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine. Chem. Pharm. Bull. 40:2251-53
60. Kageyama S, Mimoto T, Murakawa Y, Nomizu M, Ford H Jr, et al. 1993. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob. Agents Chemother. 37:810-17
61. Kageyama S, Anderson BD, Hoesterey BL, Hayashi H, Kiso Y, et al. 1994. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of us in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob. Agents Chemother. 38:1107-11
62. Gulnik SV, Suvorov LI, Liu B, Yu B, Anderson BA, et al. 1995 Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34:9282-87
63. Chang C-H, DeLoskey RL, Lam P, Schadt M, Duke J, Weber PC. 1994. Structures of cyclic ureas complexed with native and V82I mutant HIV-1 protease. 10th Int. Conf. AIDS STD, Yokohama, Jpn. p. 110A (Abstr.)
64. Erickson JW. 1993. Design and structure of symmetry-based inhibitors of HIV-1 protease. Perspect. Drug Dis. Des. 1:109-28
65. Lin Y, Lin X, Hong L, Foundling S, Heinrikson RL, et al. 1995. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. Biochemistry 34:1143-52
66. Doyon L, Poulin F, Pilote L, Clouette C, Thibeault D, et al. 1995. Protease inhibitor resistant HIV-1 variants containing an altered protease cleavage site. 2nd Natl. Conf. Hum. Retroviruses Related Infect., Washington, DC. p. 465 (Abstr.)
67. Lamarre D, Croteau G, Pilote L, Rousseau P, Doyon L. 1994. Molecular characterization of HIV-1 variants resistant to specific viral protease inhibitors. Proc. 3rd Int. Workshop HIV Drug Resist., Kauai, HI. p. 10. London: Medi-Tech Media Ltd. (Abstr.)
68. Sardana VV, Schlabach AJ, Graham P, Bush BL, Condra JH, et al. 1994. Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site. Biochemistry 33:2004-10
69. Smerdon SJ, Jager J, Wang J, Kohlstaedt LA, Chinno AJ, et al. 1994. Structure of the binding site for non-nucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 91:3911-15
70. Lacey SF, Reardon JE, Furfine ES, Kunkel TA, Bebenek K, et al. 1992. Biochemical studies on the reverse transcriptase and RNase H activities from HIV strains resistant to 3′-azido-3′ deoxythmidine. J. Biol. Chem. 267:15789-94
71. Freifeld AG, Ostrove JM. 1991. Resistance of viruses to antiviral drugs. Annu. Rev. Med. 42:247-59
72. Chatis PA, Crumpacker CS. 1992. Resistance of herpesviruses to antiviral drugs. Antimicrob. Agents Chemother. 36:1589-95
73. Biron K. 1995. Ganciclovir resistance of cytomegalovirus: mechanisms and prospects for rapid detection. Int. Antivir. News 2:117-18
74. Schechter I, Berger A. 1967. On the size of the active site in proteases. Biochem. Biophys. Res. Commun. 27:157-62